


3. The 5-member-heterocycle-fused pyridine compound, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, according to claim 1, wherein X and Z are N, Y is CH.

4. The 5-member-heterocycle-fused pyridine compound, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, according to claim 3, wherein the 5-member-heterocycle-fused pyridine compound has a structure of Formula (II),



(II)

wherein:

R₁ is substituted or unsubstituted C₆-C₂₀ aryl; substituted or unsubstituted 5- to 10-membered heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, O, and S; or substituted or unsubstituted 4- to 10-membered heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, O, and S; wherein, substituent in the substituted group is halogen, nitro, cyano, hydroxyl, unsubstituted or halogen- or morpholinyl-substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkylcarbonyl, C₁-C₆ alkoxy carbonyl, -NR_aR_b, -C(O)(NR_aR_b), unsubstituted phenyl or phenyl substituted by 1-4 of R₃, or unsubstituted 4- to 7-membered heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, O, and S, or 4- to 7-membered heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, O, and S substituted by 1-4 of R₄;

R₂ is substituted or unsubstituted C₆-C₂₀ aryl; substituted or unsubstituted 5- to 10-membered heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, O, and S; or substituted or unsubstituted 4- to 10-membered heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, O, and S; wherein, substituent in the substituted group is halogen, nitro, cyano, C₁-C₄ alkylenedioxy, unsubstituted or halogen- or -NR_cR_d-substituted C₁-C₆ alkyl or C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ sulfamido, -NR_aR_b, -C(O)R', morpholinyl, or unsubstituted or R''-substituted piperidinyl;

R₃ is halogen, nitro, cyano, C₁-C₄ alkylenedioxy, unsubstituted or halogen- or morpholinyl-substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, -NR_aR_b, -C(O)R', or morpholinyl;

R₄ is halogen, nitro, cyano, unsubstituted or halogen-substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, -NR_aR_b, -C(O)R', or unsubstituted or C₁-C₆ alkoxycarbonyl-substituted piperidinyl;

R' is C₁-C₆ alkyl, C₁-C₆ alkoxy, -NR_aR_b, or unsubstituted or halogen- or C₁-C₆ alkyl-substituted 4- to 7-membered heterocyclyl;

R'' is C₁-C₆ alkyl; C₃-C₆ cycloalkyl; C₁-C₆ alkylcarbonyl; C₁-C₆ alkoxycarbonyl; C₃-C₆ cycloalkylcarbonyl; or unsubstituted benzoyl or benzoyl substituted by substituent(s) selected from the group consisting of halogen, C₁-C₆ alkyl, and halogen-substituted C₁-C₆ alkyl;

R_a and R_b are each independently H, C₁-C₆ alkyl or C₁-C₆ alkylcarbonyl; and


R_c and R_d are each independently H or C₁-C₆ alkyl; or, R_c and R_d, together with the N atom to which they are attached, form 3- to 7-membered heterocyclyl.

5. The 5-member-heterocycle-fused pyridine compound, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, according to claim 1,

wherein, W and V are independently selected from the group consisting of H, C₁-C₄ alkyl, and C₁-C₄ alkoxy;

X and Z are N, Y is CH;

R₁ is



wherein, R_m is H, halogen, nitro, cyano; unsubstituted or halogen- or morpholinyl-substituted C₁-C₄ alkyl; C₁-C₄ alkoxy; C₁-C₄ alkylcarbonyl; C₁-C₄ alkoxycarbonyl; -NR_aR_b; -C(O)(NR_aR_b); -OC(O)-R_f, unsubstituted phenyl or phenyl substituted by 1-3 of R₃; or unsubstituted 5- to 7-membered heteroaryl containing 1-3 heteroatoms selected from the group consisting of N, O, and S or 5- to 7-membered heteroaryl containing 1-3 heteroatoms selected from the group consisting of N, O, and S substituted by 1-3 of R₄, wherein said heteroaryl is

selected from the group consisting of furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, pyranyl, pyridinyl, morpholinyl, oxazinyl, and pyrazinyl;

R₂ is cyano; C₁-C₄ alkoxy carbonyl; -NR_cR_d; substituted or unsubstituted C₆-C₂₀ aryl; substituted or unsubstituted 5- to 10-membered heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, O, and S; or substituted or unsubstituted 4- to 10-membered heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, O, and S; wherein, substituent in the substituted group is halogen, nitro, cyano, C₁-C₄ alkylendioxy, unsubstituted or halogen- or -NR_cR_d-substituted C₁-C₆ alkyl or C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ sulfamido, -NR_aR_b, -C(O)R', morpholinyl, or unsubstituted or R''-substituted piperidinyl;

R₃ is halogen, nitro, cyano, C₁-C₂ alkylendioxy, unsubstituted or halogen- or morpholinyl-substituted C₁-C₄ alkyl, C₁-C₄ alkoxy, -NR_aR_b, -C(O)R', or 4-morpholinyl;

R₄ is halogen, nitro, cyano, unsubstituted or halogen-substituted C₁-C₄ alkyl, C₁-C₄ alkoxy, -NR_aR_b, -C(O)R', 4-piperidinyl, or 1-t-butoxycarbonyl-4-piperidinyl;

R' is C₁-C₄ alkyl, C₁-C₄ alkoxy, -NR_aR_b, or 4-methylpiperazinyl;

R'' is C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₁-C₄ alkylcarbonyl, C₁-C₄ alkoxy carbonyl, C₃-C₆ cycloalkylcarbonyl, or p-trifluoromethylbenzoyl;


R_a and R_b are each independently H, C₁-C₄ alkyl or C₁-C₄ alkylcarbonyl;

R_c and R_d are each independently H or C₁-C₆ alkyl; or, R_c and R_d, together with the N atom to which they are attached, form 3- to 7-membered heterocyclyl;

R_f is C₁-C₆ alkyl or unsubstituted or halogen- or C₁-C₆ alkyl-substituted 4- to 7-membered heteroaryl, said 4- to 7-membered heteroaryl is selected from the group consisting of furanyl, pyrrolyl, and thienyl.

6. The 5-member-heterocycle-fused pyridine compound, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, according to claim 4,

wherein R₁ is



wherein, R_m is H, halogen, nitro, cyano; unsubstituted or halogen- or morpholinyl-substituted C_1 - C_4 alkyl; C_1 - C_4 alkoxy; C_1 - C_4 alkylcarbonyl; C_1 - C_4 alkoxycarbonyl; $-NR_aR_b$; $-C(O)(NR_aR_b)$; unsubstituted phenyl or phenyl substituted by 1-3 of R_3 ; or unsubstituted 5- to 7-membered heteroaryl containing 1-3 heteroatoms selected from the group consisting of N, O, and S or 5- to 7-membered heteroaryl containing 1-3 heteroatoms selected from the group consisting of N, O, and S substituted by 1-3 of R_4 , wherein said heteroaryl is selected from the group consisting of furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, pyranyl, pyridinyl, morpholinyl, oxazinyl, and pyrazinyl;

R_2 is substituted or unsubstituted C_6 - C_{20} aryl; substituted or unsubstituted 5- to 10-membered heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, O, and S; or substituted or unsubstituted 4- to 10-membered heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, O, and S; wherein, substituent in the substituted group is halogen, nitro, cyano, C_1 - C_4 alkylenedioxy, unsubstituted or halogen- or $-NR_cR_d$ -substituted C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl, C_1 - C_6 alkoxy, C_1 - C_6 sulfamido, $-NR_aR_b$, $-C(O)R'$, morpholinyl, or unsubstituted or R'' -substituted piperidinyl;

R_3 is halogen, nitro, cyano, C_1 - C_2 alkylenedioxy, unsubstituted or halogen- or morpholinyl-substituted C_1 - C_4 alkyl, C_1 - C_4 alkoxy, $-NR_aR_b$, $-C(O)R'$, or 4-morpholinyl;

R_4 is halogen, nitro, cyano, unsubstituted or halogen-substituted C_1 - C_4 alkyl, C_1 - C_4 alkoxy, $-NR_aR_b$, $-C(O)R'$, 4-piperidinyl, or 1-*t*-butoxycarbonyl-4-piperidinyl;

R' is C_1 - C_4 alkyl, C_1 - C_4 alkoxy, $-NR_aR_b$, or 4-methylpiperazinyl;


R'' is C_1 - C_4 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_4 alkylcarbonyl, C_1 - C_4 alkoxycarbonyl, C_3 - C_6 cycloalkylcarbonyl, or *p*-trifluoromethylbenzoyl;

R_a and R_b are each independently H, C_1 - C_4 alkyl or C_1 - C_4 alkylcarbonyl; and


R_c and R_d are each independently H or C_1 - C_6 alkyl; or, R_c and R_d , together with the N atom to which they are attached, form 3- to 7-membered heterocyclyl.

7. The 5-member-heterocycle-fused pyridine compound, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, according to claim 4,

wherein, R_1 is



R₂ is



wherein, R_m is H, halogen, nitro, cyano; C₁-C₄ alkyl; C₁-C₄ alkoxy; C₁-C₄ alkylcarbonyl; or C₁-C₄ alkoxy carbonyl;


R_n is H, halogen; nitro; cyano; C₁-C₂ alkylendioxy; unsubstituted or halogen-, dimethylamino-, 4-morpholinyl-, 1-aziridinyl-, 1-azetidyl-, 1-tetrahydropyrrolyl-, 1-piperidinyl- or 1-homopiperidinyl-substituted C₁-C₄ alkyl; C₁-C₄ alkoxy; C₁-C₄ sulfamido; -NR_aR_b; -C(O)R'; 4-morpholinyl; or unsubstituted or R''-substituted piperidinyl;

R' is C₁-C₄ alkyl, C₁-C₄ alkoxy, -NR_aR_b, or 4-methylpiperazinyl;

R'' is C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₁-C₄ alkylcarbonyl, C₁-C₄ alkoxy carbonyl, C₃-C₆ cycloalkylcarbonyl, or p-trifluoromethylbenzoyl; and

R_a and R_b are each independently H, C₁-C₄ alkyl or C₁-C₄ alkylcarbonyl.

8. The 5-member-heterocycle-fused pyridine compound, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, according to claim 4, wherein



wherein, R_m is H, halogen, nitro, hydroxyl, C₁-C₄ alkoxy, unsubstituted phenyl or phenyl substituted by 1-3 of R₃, or unsubstituted 5- to 7-membered heteroaryl containing 1-3 heteroatoms selected from the group consisting of N, O, and S, or 5- to 7-membered heteroaryl

containing 1-3 heteroatoms selected from the group consisting of N, O, and S substituted by 1-3 of R₄, wherein said heteroaryl is selected from the group consisting of furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, pyranyl, pyridinyl, morpholinyl, oxazinyl, and pyrazinyl;

R_n is H, halogen; nitro; cyano; unsubstituted or halogen-, dimethylamino-, 4-morpholinyl-, 1-aziridinyl-, 1-azetidiny-, 1-tetrahydropyrrolyl-, 1-piperidinyl- or 1-homopiperidinyl-substituted C₁-C₄ alkyl; C₁-C₄ alkoxy; C₁-C₄ sulfamido; -NR_aR_b; -C(O)R'; 4-morpholinyl; or unsubstituted or R''-substituted piperidinyl;

R₃ is halogen, nitro, cyano, C₁-C₄ alkylendioxy, unsubstituted or halogen- or morpholinyl-substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, -NR_aR_b, -C(O)R', or morpholinyl;


R₄ is halogen, nitro, cyano, unsubstituted or halogen-substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, -NR_aR_b, -C(O)R', or unsubstituted or C₁-C₆ alkoxycarbonyl-substituted piperidinyl;

R' is C₁-C₄ alkyl, C₁-C₄ alkoxy, -NR_aR_b, or 4-methylpiperazinyl;

R'' is C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₁-C₄ alkylcarbonyl, C₁-C₄ alkoxycarbonyl, C₃-C₆ cycloalkylcarbonyl, or p-trifluoromethylbenzoyl; and

R_a and R_b are independently H, C₁-C₄ alkyl or C₁-C₄ alkylcarbonyl.

9. The 5-member-heterocycle-fused pyridine compound, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, according to claim 1, wherein, the 5-member-heterocycle fused pyridine compound is selected from the group consisting of the following compounds:



halogen, nitro, cyano, C₁-C₄ alkylenedioxy, unsubstituted or halogen- or -NR_cR_d-substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ sulfamido, -NR_aR_b, -C(O)R', morpholinyl, or unsubstituted or R''-substituted piperidinyl;

wherein, R₃ is halogen, nitro, cyano, C₁-C₄ alkylenedioxy, unsubstituted or halogen- or morpholinyl-substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, -NR_aR_b, -C(O)R', or morpholinyl;

R₄ is halogen, nitro, cyano, unsubstituted or halogen-substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, -NR_aR_b, -C(O)R', or unsubstituted or C₁-C₆ alkoxycarbonyl-substituted piperidinyl;


R' is C₁-C₆ alkyl, C₁-C₆ alkoxy, -NR_aR_b, or unsubstituted or halogen- or C₁-C₆ alkyl-substituted 4- to 7-membered heterocyclyl;

R'' is C₁-C₆ alkyl; C₃-C₆ cycloalkyl; C₁-C₆ alkylcarbonyl; C₁-C₆ alkoxycarbonyl; C₃-C₆ cycloalkylcarbonyl; or unsubstituted benzoyl or benzoyl substituted by substituent(s) selected from the group consisting of halogen, C₁-C₆ alkyl, and halogen-substituted C₁-C₆ alkyl;

R_a and R_b are each independently H or C₁-C₆ alkyl;

R_c and R_d are each independently H or C₁-C₆ alkyl; or, R_c and R_d, together with the N atom to which they are attached, form 3- to 7-membered heterocyclyl.

12. The pharmaceutical composition of claim 10, wherein the 5-member-heterocycle-fused pyridine compound has a structure of Formula (II),



(II)

wherein:

R₁ is substituted or unsubstituted C₆-C₂₀ aryl; substituted or unsubstituted 5- to 10-membered heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, O, and S; or substituted or unsubstituted 4- to 10-membered heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, O, and S; wherein, substituent in the substituted group is halogen, nitro, cyano, hydroxyl, unsubstituted or halogen- or morpholinyl-substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkylcarbonyl, C₁-C₆ alkoxycarbonyl, -NR_aR_b, -C(O)(NR_aR_b),

unsubstituted phenyl or phenyl substituted by 1-4 of R₃, or unsubstituted 4- to 7-membered heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, O, and S, or 4- to 7-membered heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, O, and S substituted by 1-4 of R₄;

R₂ is substituted or unsubstituted C₆-C₂₀ aryl; substituted or unsubstituted 5- to 10-membered heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, O, and S; or substituted or unsubstituted 4- to 10-membered heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, O, and S; wherein, substituent in the substituted group is halogen, nitro, cyano, C₁-C₄ alkylenedioxy, unsubstituted or halogen- or -NR_cR_d-substituted C₁-C₆ alkyl or C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ sulfamido, -NR_aR_b, -C(O)R', morpholinyl, or unsubstituted or R''-substituted piperidinyl;

R₃ is halogen, nitro, cyano, C₁-C₄ alkylenedioxy, unsubstituted or halogen- or morpholinyl-substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, -NR_aR_b, -C(O)R', or morpholinyl;

R₄ is halogen, nitro, cyano, unsubstituted or halogen-substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, -NR_aR_b, -C(O)R', or unsubstituted or C₁-C₆ alkoxycarbonyl-substituted piperidinyl;

R' is C₁-C₆ alkyl, C₁-C₆ alkoxy, -NR_aR_b, or unsubstituted or halogen- or C₁-C₆ alkyl-substituted 4- to 7-membered heterocyclyl;

R'' is C₁-C₆ alkyl; C₃-C₆ cycloalkyl; C₁-C₆ alkylcarbonyl; C₁-C₆ alkoxycarbonyl; C₃-C₆ cycloalkylcarbonyl; or unsubstituted benzoyl or benzoyl substituted by substituent(s) selected from the group consisting of halogen, C₁-C₆ alkyl, and halogen-substituted C₁-C₆ alkyl;

R_a and R_b are each independently H, C₁-C₆ alkyl or C₁-C₆ alkylcarbonyl; and

R_c and R_d are each independently H or C₁-C₆ alkyl; or, R_c and R_d, together with the N atom to which they are attached, form 3- to 7-membered heterocyclyl.

13. The pharmaceutical composition of claim 10, wherein


X and Z are N, Y is CH;

W and V are independently selected from the group consisting of H, C₁-C₄ alkyl, and C₁-C₄ alkoxy;

R₁ is

R_f is C_1 - C_6 alkyl or unsubstituted or halogen- or C_1 - C_6 alkyl-substituted 4- to 7-membered heteroaryl, said 4- to 7-membered heteroaryl is selected from the group consisting of furanyl, pyrrolyl, and thienyl.

14. The pharmaceutical composition of claim 12 or 13, wherein



wherein, R_m is H, halogen, nitro, hydroxyl, C_1 - C_4 alkoxy, unsubstituted phenyl or phenyl substituted by 1-3 of R_3 , or unsubstituted 5- to 7-membered heteroaryl containing 1-3 heteroatoms selected from the group consisting of N, O, and S, or 5- to 7-membered heteroaryl containing 1-3 heteroatoms selected from the group consisting of N, O, and S substituted by 1-3 of R_4 , wherein said heteroaryl is selected from the group consisting of furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, pyranyl, pyridinyl, morpholinyl, oxazinyl, and pyrazinyl;

R_n is H, halogen; nitro; cyano; unsubstituted or halogen-, dimethylamino-, 4-morpholinyl-, 1-aziridinyl-, 1-azetidiny-, 1-tetrahydropyrrolyl-, 1-piperidinyl- or 1-homopiperidinyl-substituted C_1 - C_4 alkyl; C_1 - C_4 alkoxy; C_1 - C_4 sulfamido; $-NR_aR_b$; $-C(O)R'$; 4-morpholinyl; or unsubstituted or R'' -substituted piperidinyl;

R_3 is halogen, nitro, cyano, C_1 - C_2 alkylendioxy, unsubstituted or halogen- or morpholinyl-substituted C_1 - C_4 alkyl, C_1 - C_4 alkoxy, $-NR_aR_b$, $-C(O)R'$, or 4-morpholinyl;



















R_4 is halogen, nitro, cyano, unsubstituted or halogen-substituted C_1 - C_4 alkyl, C_1 - C_4 alkoxy, $-NR_aR_b$, $-C(O)R'$, 4-piperidinyl, or 1-t-butoxycarbonyl-4-piperidinyl;


R' is C_1 - C_4 alkyl, C_1 - C_4 alkoxy, $-NR_aR_b$, or 4-methylpiperazinyl;
















R'' is C_1 - C_4 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_4 alkylcarbonyl, C_1 - C_4 alkoxy carbonyl, C_3 - C_6 cycloalkylcarbonyl, or p-trifluoromethylbenzoyl; and













R_a and R_b are independently H, C_1 - C_4 alkyl or C_1 - C_4 alkylcarbonyl.
















15. The pharmaceutical composition of claim 10, wherein the compound is selected from the group consisting of :
















































































16. A 5-member-heterocycle-fused pyridine compound, pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof according to any one of claims 1 to 9 or a pharmaceutical composition according to any one of claims 10 to 15 for use in a method of preventing or treating diseases associated with abnormal cell proliferation, morphological change and hyperkinesis related to abnormal protein tyrosine kinase, or diseases related to angiogenesis or metastasis, in a subject in need thereof, said method comprises administering a prophylactically or therapeutically effective amount of said compound or said pharmaceutical composition.

17. The use according to claim 16, wherein the disease associated with abnormal cell proliferation related to abnormal protein tyrosine is a disease associated with abnormal cell proliferation related to abnormal c-Met, and wherein the disease associated with abnormal cell proliferation related to abnormal c-Met is a cancer associated with over-expression or over-activation of c-Met.